| These highlights do not include all the information needed to use SOLIQUA 100/33 safely and effectively . See full prescribing information for SOLIQUA 100/33. SOLIQUA ® 100/33 (insulin glargine and lixisenatide) injection, for subcutaneous use Initial U.S. Approval: 2016 | Sanofi-Aventis U.S. LLC | Sanofi-Aventis Deutschland GmbH | 20260318 | 25 |
| These highlights do not include all the information needed to use BASAGLAR safely and effectively. See full prescribing information for BASAGLAR BASAGLAR (insulin glargine) injection, for subcutaneous use Initial U.S. Approval: 2015 | Eli Lilly and Company | 20251211 | 34 |
| These highlights do not include all the information needed to use INSULIN GLARGINE-YFGN safely and effectively. See full prescribing information for INSULIN GLARGINE-YFGN. INSULIN GLARGINE-YFGN injection, for subcutaneous use Initial U.S. Approval: 2021 Insulin glargine-yfgn is a biosimilar* to LANTUS (insulin glargine). | Civica, Inc. | BIOCON SDN.BHD. | 20250724 | 1 |
| These highlights do not include all the information needed to use INSULIN GLARGINE-YFGN safely and effectively. See full prescribing information for INSULIN GLARGINE-YFGN. INSULIN GLARGINE-YFGN injection, for subcutaneous use Initial U.S. Approval: 2021 Insulin glargine-yfgn is a biosimilar* to LANTUS (insulin glargine). | Civica, Inc. | BIOCON SDN.BHD. | 20250703 | 1 |
| These highlights do not include all the information needed to use LANTUS safely and effectively. See full prescribing information for LANTUS. LANTUS ® (insulin glargine) injection, for subcutaneous use Initial U.S. Approval: 2000 | sanofi-aventis U.S. LLC | Sanofi S.r.l. | Sanofi-Aventis Deutschland GmbH | 20250602 | 35 |
| These highlights do not include all the information needed to use INSULIN GLARGINE, U-300 safely and effectively. See full prescribing information for INSULIN GLARGINE, U-300. INSULIN GLARGINE, U-300, injection, for subcutaneous use Initial U.S. Approval: 2015 This product is TOUJEO ® (insulin glargine). | Sanofi-Aventis U.S. LLC | Genzyme Corporation | Sanofi-Aventis Deutschland GmbH | 20250530 | 7 |
| These highlights do not include all the information needed to use TOUJEO ® U-300 safely and effectively. See full prescribing information for TOUJEO ® U-300. TOUJEO U-300 (insulin glargine) injection, for subcutaneous use Initial U.S. Approval: 2015 | Sanofi-Aventis U.S. LLC | Sanofi-Aventis Deutschland GmbH | Genzyme Corporation | 20250530 | 25 |
| These highlights do not include all the information needed to use INSULIN GLARGINE-YFGN safely and effectively. See full prescribing information for INSULIN GLARGINE-YFGN. INSULIN GLARGINE-YFGN injection, for subcutaneous use Initial U.S. Approval: 2021 This product is SEMGLEE (insulin glargine-yfgn). SEMGLEE (insulin glargine-yfgn) is biosimilar* to LANTUS (insulin glargine). | Biocon Biologics Inc. | 20250303 | 8 |
| These highlights do not include all the information needed to use SEMGLEE safely and effectively. See full prescribing information for SEMGLEE. SEMGLEE ® (insulin glargine-yfgn) injection, for subcutaneous use Initial U.S. Approval: 2021 SEMGLEE ® (insulin glargine-yfgn) is biosimilar* to LANTUS (insulin glargine). | Biocon Biologics Inc. | BIOCON SDN.BHD. | 20250303 | 14 |
| These highlights do not include all the information needed to use REZVOGLAR safely and effectively. See full prescribing information for REZVOGLAR. REZVOGLAR (insulin glargine-aglr) injection, for subcutaneous use Initial U.S. Approval: 2021 REZVOGLAR (insulin glargine-aglr) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningfu | Eli Lilly and Company | 20240809 | 7 |
| These highlights do not include all the information needed to use Insulin glargine safely and effectively. See full prescribing information for Insulin glargine. Insulin glargine injection, for subcutaneous injection Initial U.S. Approval: 2000 | A-S Medication Solutions | 20231101 | 3 |
| These highlights do not include all the information needed to use LANTUS safely and effectively. See full prescribing information for LANTUS. LANTUS ® (insulin glargine) injection, for subcutaneous use Initial U.S. Approval: 2000 | A-S Medication Solutions | 20230722 | 6 |
| These highlights do not include all the information needed to use TOUJEO U-300 safely and effectively. See full prescribing information for TOUJEO ® U-300. TOUJEO U-300 (insulin glargine) injection, for subcutaneous use Initial U.S. Approval: 2015 | A-S Medication Solutions | 20230712 | 9 |
| These highlights do not include all the information needed to use LANTUS safely and effectively. See full prescribing information for LANTUS. LANTUS ® (insulin glargine) injection, for subcutaneous use Initial U.S. Approval: 2000 | A-S Medication Solutions | 20230606 | 13 |
| These highlights do not include all the information needed to use REZVOGLAR safely and effectively. See full prescribing information for REZVOGLAR. REZVOGLAR (insulin glargine-aglr) injection, for subcutaneous use Initial U.S. Approval: 2021 REZVOGLAR (insulin glargine-aglr) is interchangeable An interchangeable product (IP) is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product (RP) and that there are no clinically meaningful diff | A-S Medication Solutions | 20230502 | 1 |
| These highlights do not include all the information needed to use TOUJEO U-300 safely and effectively. See full prescribing information for TOUJEO ® U-300. TOUJEO U-300 (insulin glargine) injection, for subcutaneous use Initial U.S. Approval: 2015 | A-S Medication Solutions | 20230427 | 13 |
| These highlights do not include all the information needed to use LANTUS safely and effectively. See full prescribing information for LANTUS. LANTUS ® (insulin glargine) injection, for subcutaneous use Initial U.S. Approval: 2000 | A-S Medication Solutions | 20230204 | 12 |
| These highlights do not include all the information needed to use LANTUS safely and effectively. See full prescribing information for LANTUS. LANTUS (insulin glargine [rDNA origin] injection) solution for subcutaneous injection Initial U.S. Approval: 2000 | TYA Pharmaceuticals | 20140109 | 2 |
| These highlights do not include all the information needed to use LANTUS safely and effectively. See full prescribing information for LANTUS. LANTUS (insulin glargine [rDNA origin] injection) solution for subcutaneous injection Initial U.S. Approval: 2000 | Dispensing Solutions, Inc. | 20110920 | 1 |
| These highlights do not include all the information needed to use LANTUS safely and effectively. See full prescribing information for LANTUS. LANTUS (insulin glargine [rDNA origin] injection) solution for subcutaneous injection Initial U.S. Approval: 2000 | Physicians Total Care, Inc. | 20100105 | 2 |